Hims and Hers Health Inc vs QXO Inc. Common Stock — how do they compare? Hims and Hers Health Inc trades at $27.36 (market cap $6.93B), while QXO Inc. Common Stock trades at $10.33 (market cap $11.43B). The key difference: QXO Inc. Common Stock is the larger of the two by market cap, and Hims and Hers Health Inc is trading nearer its 52-week high, QXO Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and QXO Inc. Common Stock for 0 Days on average.
| HIMS | QXO | |
|---|---|---|
Market Cap | $6.93B | $11.43B |
Volume | 9,771,956 | 21,645,941 |
Sector | Health | Industrials |
52-Week High | $62.76 | $27.07 |
52-Week Low | $14.52 | $10.33 |
Typical Hold Time | 21 Days | 0 Days |
Enterprise Value | $7.64B | $16.75B |
Signals from Pluang's Aura AI — not financial advice
HIMS trades at $29.71, down 3.04% today, amid ongoing securities class action lawsuits. The stock shows bullish technical signals with strong moving average support and key resistance at $32. Fundamentally, while revenue grew to $2.35B in 2025, the company posted a net loss of -$142M in 2026 with negative profit margins, though it maintains a solid gross margin of 68.4%.
The investment outlook is mixed: technical indicators suggest near-term upside potential toward the $32.17 consensus target, but fundamental weakness and legal overhangs pose significant risks. Analyst sentiment leans cautious with 65% hold ratings, reflecting concerns about profitability and regulatory challenges despite growth prospects.
QXO trades at $11.02, up 3.57% on the day but down significantly year-to-date amid weak residential demand and integration challenges from its TopBuild acquisition. The stock shows neutral technical signals with support near $10-$11 and resistance at $12. Fundamentally, revenue grew to $6.84B in 2025 but net losses deepened to $279.4M, with a negative profit margin of -5.17% in 2026. Analyst sentiment remains bullish with a $22.89 consensus target, though recent news highlights margin pressure and execution risks.
The outlook hinges on successful integration of acquisitions and EBITDA growth targets, but high execution risk, negative earnings, and sector headwinds pose substantial downside. With 100% buy ratings from analysts and institutional accumulation, patient investors may see upside if management delivers on its playbook, though volatility is expected near-term.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →QXO, Inc. is a distributor of roofing, insulation, waterproofing, and other building materials, serving contractors and builders across US and Canada through its network of branch locations.
Read more on QXO →